初始免疫抑制方案对免疫低危肾移植患者长期结局的影响
基于PROCARE队列(n=4724)中排除既往移植、术前DSA及诱导治疗的患者,比较三种初始免疫抑制方案的长期结局。TAC/MMF/Pred组10年死亡删失移植物存活率79%,与CsA/MMF/Pred组82%(P=0.88)和CsA/Pred组79%(P=0.21)无显著差异;但1年无排斥存活率TAC/MMF/Pred组81%显著高于CsA/MMF/Pred组67%(P<0.0001)和CsA/Pred组64%(P<0.0001)。
要点
- 免疫低危肾移植患者中,CsA或TAC联合或不联合MMF的10年移植物存活率无显著差异。
- TAC/MMF/Pred方案1年无排斥存活率显著优于含CsA方案。
- 初始免疫抑制方案选择不影响免疫低危患者长期移植物存活。
核心结论
- 在免疫低危肾移植患者中,无论初始免疫抑制方案为CsA或TAC、联合或不联合MMF,均可获得优异的长期移植物存活,尽管1年无排斥存活率存在差异。
研究设计与样本
- 基于PROCARE队列(荷兰多中心研究,纳入1995-2005年所有肾移植且有术前血清者,n=4724)的回顾性分析。
- 排除既往肾移植、术前DSA阳性或接受诱导治疗的患者,最终分析三种方案:CsA/Pred(n=542)、CsA/MMF/Pred(n=857)、TAC/MMF/Pred(n=811)。
主要发现
- 10年死亡删失移植物存活率:TAC/MMF/Pred组79%,CsA/MMF/Pred组82%(P=0.88),CsA/Pred组79%(P=0.21),协变量校正后无显著差异。
- 1年无排斥存活率(删失死亡及非排斥相关失败):TAC/MMF/Pred组81%,显著高于CsA/MMF/Pred组67%(P<0.0001)和CsA/Pred组64%(P<0.0001)。
临床怎么用
- 对于免疫低危肾移植患者,初始免疫抑制方案的选择可个体化,不必因长期移植物存活差异而强制选择某一方案。
- TAC/MMF/Pred方案可显著降低1年排斥风险,但长期移植物存活与含CsA方案相当。
局限性
- 研究基于历史队列(1995-2005年),可能不反映当前免疫抑制实践。
- 排除了接受诱导治疗的患者,结论不适用于诱导治疗人群。
- 为回顾性分析,可能存在未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few studies have evaluated the effect of different immunosuppressive strategies on long-term kidney transplant outcomes. Moreover, as they were usually based on historical data, it was not possible to account for the presence of pretransplant donor-specific human-leukocyte antigen antibodies (DSA), a currently recognized risk marker for impaired graft survival. The aim of this study was to evaluate to what extent frequently used initial immunosuppressive therapies increase graft survival in immunological low-risk patients. METHODS: We performed an analysis on the PROCARE cohort, a Dutch multicentre study including all transplantations performed in the Netherlands between 1995 and 2005 with available pretransplant serum (n = 4724). All sera were assessed for the presence of DSA by a luminex single-antigen bead assay. Patients with a previous kidney transplantation, pretransplant DSA or receiving induction therapy were excluded from the analysis. RESULTS: Three regimes were used in over 200 patients: cyclosporine (CsA)/prednisolone (Pred) (n = 542), CsA/mycophenolate mofetil (MMF)/Pred (n = 857) and tacrolimus (TAC)/MMF/Pred (n = 811). Covariate-adjusted analysis revealed no significant differences in 10-year death-censored graft survival between patients on TAC/MMF/Pred therapy (79%) compared with patients on CsA/MMF/Pred (82%, P = 0.88) or CsA/Pred (79%, P = 0.21). However, 1-year rejection-free survival censored for death and failure unrelated to rejection was significantly higher for TAC/MMF/Pred (81%) when compared with CsA/MMF/Pred (67%, P < 0.0001) and CsA/Pred (64%, P < 0.0001). CONCLUSION: These results suggest that in immunological low-risk patients excellent long-term kidney graft survival can be achieved irrespective of the type of initial immunosuppressive therapy (CsA or TAC; with or without MMF), despite differences in 1-year rejection-free survival.
引用
- Michielsen LA, van Zuilen AD, Verhaar MC, et al. Effect of initial immunosuppression on long-term kidney transplant outcome in immunological low-risk patients. Nephrol Dial Transplant. 2019. PMID: 30561730. doi:10.1093/ndt/gfy377
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。